During the 36-to 48-hour admission, supine and erect blood pressures were measured at 4-hourly intervals. In addition the observers in the trial (D.B.G. or J.C.P.) measured the blood pressures with Hawksley randomzero sphygmomanometers on two occasions -on the evening of admission (20.00 to 2I.00 hours); and after a io-hour overnight period of complete bed-rest (o8.oo to og.oo hours). On both these occasions the number of i2-inch steps required to produce an increment of standing pulse of 30 beats a minute was determined using electrocardiographic control. The patients were invited to participate in the trial if the morning supine diastolic pressures (D.B.G. or J.C.P.) were over 90 to 95 mmHg and under I05 mmHg, and other out-patient and ward readings confirmed persistently raised blood pressure readings. At least 35 blood pressure readings were available for each patient.
After four weeks of therapy, each of the active treatments was significantly superior to treatment with placebo. There was a trendfor treatment with practolol alone to reduce the blood pressure more than bendrofluazide alone in all positions but this was not statistically significant after four weeks of treatment. The maximum reduction in supine blood pressure was achieved with combined therapy of practolol with bendrofluazide (mean blood pressure I38 9/90o5 mmHg). The combined therapy was significantly superior to bendrofluazide alone in allpositions but was superior to practolol alone onlyfor supine and erect systolic blood pressures. The reductions in blood pressure achieved during the period on combined therapy were not significantly greater than the sum of the reductions obtained in the periods when the individual drugs were given separately.
This study shows that practolol either alone or in combination with bendrofluazide is a useful addition to the range of antihypertensive drugs. During the 36-to 48-hour admission, supine and erect blood pressures were measured at 4-hourly intervals. In addition the observers in the trial (D.B.G. or J.C.P.) measured the blood pressures with Hawksley randomzero sphygmomanometers on two occasions -on the evening of admission (20.00 to 2I.00 hours); and after a io-hour overnight period of complete bed-rest (o8.oo to og.oo hours). On both these occasions the number of i2-inch steps required to produce an increment of standing pulse of 30 beats a minute was determined using electrocardiographic control. The patients were invited to participate in the trial if the morning supine diastolic pressures (D.B.G. or J.C.P.) were over 90 to 95 mmHg and under I05 mmHg, and other out-patient and ward readings confirmed persistently raised blood pressure readings. At least 35 blood pressure readings were available for each patient.
A total of 24 patients from the original 57 satisfied the criteria for inclusion in the study. The nature of the trial was explained and all gave their consent. There were I2 men and I2 women, age range 24 to 64 (mean 47 4) years. Before discharge from hospital they were familiarized with a standard sequence of questions about general health and the occurrence and severity of a number of symptoms. The methods of access to the doctors conducting the study were also outlined. 
Discussion
The study shows that practolol, 400 mg/day was as effective as bendrofluazide, 5 mg/day in lowering supine, erect, and post-exercise systolic and diastolic blood pressures in patients with mild hypertension. After two weeks of treatment practolol significantly lowered blood pressure in all positions in comparison with placebo, in contrast to bendrofluazide which did not produce significant reduction in supine and post-exercise diastolic pressures. The combination of practolol with bendrofluazide achieved a satisfactory reduction in blood pressure to a mean supine blood pressure of I39/9I mmnHg.
The combination was better than practolol alone only in the reduction of supine and erect systolic blood pressures but was superior to bendrofluazide alone in all positions after four weeks of therapy. There was no evidence of interaction (synergism) between practolol and bendrofluazide as the effects of the drugs in combination were not significantly greater than the sum of the effects of the individual drugs given separately.
The criteria for patient selection appear to have been satisfactory for the purposes of the study because blood pressures on entry to the trial were not statistically different from readings in the placebo period. Inaddition there was no statistically significant fall in the mean blood pressures for each period (I-*4) as the trial progressed. Nevertheless there was a trend for the mean period blood pressures to fall and this may be related to several factors including further familiarization with the trial routine, overall weight loss of the group of patients, and, in the case of post-exercise blood pressures, to increased experience and training with the specified exercise load for each patient. The number of patients excluded from the trial because of the strict selection routine suggests that many patients are being treated, and perhaps included in clinical trials, who do not have sustained hypertension. 
